Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;28(1):220-222.
doi: 10.1038/s41391-023-00778-9. Epub 2024 Jan 3.

Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board

Stacy Loeb  1 , Heather H Cheng  2 , Channing J Paller  3 , Emily Weg  4 , Jennifer Johnson  5 , Laura Gross  6 , Scott W Keith  7 , Jessica Russo  8 , Feighanne Hathaway  9 , Adrian Rivera  10 , Veda N Giri  6
Affiliations

Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board

Stacy Loeb et al. Prostate Cancer Prostatic Dis. 2025 Mar.

Abstract

Background: Germline testing is important in prostate cancer and evaluation can be complex.

Methods: We instituted a monthly multi-disciplinary virtual genetics tumor board (7/2021-3/2022). Participants and panelists were surveyed on usefulness and acceptability.

Results: 101 participants attended a session, and 77 follow-up surveys were completed. Over 90% participants and 100% panelists endorsed usefulness of the case discussions and usability of the technology. The majority felt it provided new information they will use.

Conclusions: A multidisciplinary genetics board was successfully developed to address complexity in prostate cancer genetics. The virtual platform may enhance dissemination of expertise where there are regional gaps.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SL reports prior equity in Gilead, unrelated to this publication. HHC reports research funding to institution from Astellas, Clovis Oncology, Color Foundation, Janssen, Medivation, Promontory Therapeutics, Sanofi; Consultant to AstraZeneca; Royalties from UpToDate. CJP reports consulting for Bayer. FH reports educational consultant for AstraZeneca. The remaining authors report no relevant COI.

Similar articles

See all similar articles

Cited by

References

    1. Loeb S, Giri VN. Clinical implications of germline testing in newly diagnosed prostate cancer. Eur Urol Oncol. 2021;4:1–9. - DOI - PubMed
    1. Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, et al. Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium. Clin Genitourin Cancer. 2019;17:275–82.e271. - DOI - PubMed - PMC
    1. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. - DOI - PubMed
    1. Hijazi MA, Prebay ZJ, Johnson A, Wilder S, Patel A, Mehra R, et al. Utilization of a virtual tumor board for the care of patients with renal masses: experience from a quality improvement collaborative. Urol Pract. 2023;10:380–8. - DOI - PubMed
    1. Valerio MR, Serretta V, Arico D, Fazio I, Altieri V, Baldari S, et al. A prospective observational study on the structuring process and implementation of a large regional, inter-hospital, virtual multidisciplinary tumor board on prostate cancer. Anticancer Res. 2023;43:501–8. - DOI - PubMed

LinkOut - more resources